Atrium Therapeutics, Inc. (RNA) — Financial statements

Income statement, balance sheet, and cash flow for Atrium Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.

Metric (USD Millions)	2025
Revenue & Gross Profit
Revenue	19
Cost of Revenue	0.00
Gross Profit	19
Operating Expenses
R&D Expenses	54
General & Administrative Expenses	42
Selling & Marketing Expenses	0.00
SG&A Expenses	42
Other Expenses	0.00
Operating Expenses	95
Total Costs & Expenses	95
Operating Results
Operating Income	-77
Depreciation & Amortization	0.32
EBITDA	-76
EBIT	-77
Interest & Other Income
Net Interest Income	0.00
Interest Income	0.00
Interest Expense	0.00
Non-Operating Income	0.00
Other Income / Expenses	-0.01
Income Before Tax	-77
Income Tax Expense	-0.14
Net Income & EPS
Net Income from Continuing Operations	-77
Net Income from Discontinued Operations	0.00
Net Income	-77
Bottom-Line Net Income	-77
EPS (Basic)	-4.48
EPS (Diluted)	-4.48
Weighted Average Shares	17
Weighted Average Diluted Shares	17

* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.

Income statement, balance sheet, and cash flow for Atrium Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.

Metric (USD Millions)	2025
Revenue & Gross Profit
Revenue	19
Cost of Revenue	0.00
Gross Profit	19
Operating Expenses
R&D Expenses	54
General & Administrative Expenses	42
Selling & Marketing Expenses	0.00
SG&A Expenses	42
Other Expenses	0.00
Operating Expenses	95
Total Costs & Expenses	95
Operating Results
Operating Income	-77
Depreciation & Amortization	0.32
EBITDA	-76
EBIT	-77
Interest & Other Income
Net Interest Income	0.00
Interest Income	0.00
Interest Expense	0.00
Non-Operating Income	0.00
Other Income / Expenses	-0.01
Income Before Tax	-77
Income Tax Expense	-0.14
Net Income & EPS
Net Income from Continuing Operations	-77
Net Income from Discontinued Operations	0.00
Net Income	-77
Bottom-Line Net Income	-77
EPS (Basic)	-4.48
EPS (Diluted)	-4.48
Weighted Average Shares	17
Weighted Average Diluted Shares	17

* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.